Indian Drug Discovery Informatics Market 2026-2035

India Drug Discovery Informatics Market Size, Share & Trends Analysis Report by Function (Docking, Molecular Modeling, Libraries & Database Preparation, Sequencing & Target Data Analysis, and Others), By End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Others), Forecast Period (2026-2035)

Industry Overview

India drug discovery informatics market was valued at $69.7 million in 2025 and is projected to reach $207.7 million by 2035, growing at a CAGR of 11.6% during the forecast period (2026–2035). The India drug discovery informatics market is expanding as research organizations and pharmaceutical companies increase their reliance on digital tools to strengthen early-stage development. Major domestic players are integrating advanced computational platforms to improve target identification, streamline screening processes, and enhance data accuracy. Growing investment in AI-driven modeling and cloud-based analytics is supporting faster decision-making within drug discovery programs. Government initiatives promoting biotech innovation and digital healthcare infrastructure are further accelerating adoption. Companies are also collaborating with technology providers to modernize research workflows and improve interoperability across systems. Together, these developments are reinforcing sustained growth in India’s drug discovery informatics ecosystem

Market Dynamics

Growing Adoption of Computational Research Tools Across India’s Life Sciences Sector

India’s drug discovery informatics market is gaining momentum as research institutions and pharmaceutical companies increasingly shift toward data-driven development practices. Leading domestic firms are integrating advanced platforms for molecular modeling, virtual screening, and predictive analytics to strengthen early-stage discovery. This transition is helping teams manage complex datasets more efficiently while improving accuracy in target identification and compound prioritization. Partnerships between software providers and R&D organizations are further accelerating the integration of scalable digital solutions. The trend reflects India’s broader move toward modernized, technology-enabled research environments.

Strengthening Ecosystem for AI-Enabled Drug Discovery and Collaborative Innovation

AI- and ML-based tools are becoming more prominent across India’s discovery workflows, enhancing capabilities in simulation, hit-to-lead optimization, and multi-omics analysis. Biotech startups and established pharmaceutical companies are increasingly collaborating with technology partners to develop customized informatics systems that align with local research priorities. These advancements are reducing development timelines and supporting more precise molecule design. Government programs promoting biotechnology innovation and digital health infrastructure are also contributing to rising adoption. Collectively, these developments indicate India’s growing commitment to expanding its footprint in computational drug discovery and informatics-driven research.

Market Segmentation

• Based on the function, the market is segmented into docking, molecular modeling, libraries & database preparation, sequencing & target data analysis, and others.
• Based on the end-user, the market is segmented into pharmaceutical & biotechnology companies, contract research organizations, and others.

Docking Segment to Lead the Market with the Largest Share

In India, the docking segment is establishing itself as a central component of the drug discovery informatics landscape, supported by the country’s expanding research activity and growing emphasis on computational screening. Academic institutions, pharmaceutical companies, and biotech startups are increasingly relying on docking tools to narrow vast chemical libraries and assess ligand–target interactions with greater precision. This reliance helps shorten early development cycles and minimize laboratory-intensive testing. Advancements in AI-assisted scoring, cloud-enabled processing, and improved visualization are further strengthening the appeal of docking platforms among Indian researchers. As the nation accelerates its shift toward digitally supported discovery methodologies, the docking segment continues to hold the largest share within the functional market

Pharmaceutical & Biotechnology Companies: A Key Segment in Market Growth

Pharmaceutical and biotechnology companies in India remain the leading contributors to the adoption of drug discovery informatics solutions. These organizations are prioritizing digital tools to streamline target discovery, enhance lead optimization, and support data-rich decision-making across R&D workflows. With India’s biopharma landscape expanding into areas such as biologics, biosimilars, and novel therapeutic modalities, integrated informatics platforms are becoming essential for maintaining development efficiency and competitiveness. Companies are also advancing internal digital transformation programs, incorporating AI-driven analytics and cloud-based systems to manage increasingly complex datasets. Collectively, these efforts position pharmaceutical and biotechnology firms as the most influential end-user segment driving market growth in India.

Market Players Outlook

The major companies operating in the India drug discovery informatics market include Accenture plc, Infosys Limited, PerkinElmer, Inc, Syngene International Limited, Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In July 2025, VedTechBio Research Pvt Ltd in collaboration with the U.S.-based AlphaMeld Corporation announced a partnership to apply AI-enabled drug discovery across preclinical stages in India. This alliance aims to bring generative-AI capabilities and translational readiness to early-stage drug programs.
• In March 2025, a manufacturing and analytics services provider, Aurigene Pharmaceutical Services Ltd. (the CDMO arm of a major Indian pharmaceutical group), launched an end-to-end AI- and ML-assisted drug discovery platform, signalling growing adoption of informatics workflows among established players.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the India drug discovery informatics market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.

Show more